Objective: We calculated in a referral population of term and near-term infants with hypoxic respiratory failure (HRF) as a primary presenting problem the overall survival rate, the need for extracorporeal membrane oxygenation (ECMO) and the incidence of apparently irreversible disorders.
Introduction
Term and near-term infants with hypoxic respiratory failure (HRF) occurring as a result of etiologies such as persistent pulmonary hypertension of the newborn (PPHN), meconium aspiration syndrome (MAS), respiratory distress syndrome (RDS) or congenital or aspiration pneumonias of any etiology, continue to be important contributors to neonatal morbidity and mortality. Angus et al. 1 demonstrated that this population of infants generates a substantial number of ventilator days as judged by New York and California data. In spite of the economic and public health importance of this group of infants, few data have been published to provide benchmarks for outcomes. Few attempts have also been made in the infants who die with or of HRF to differentiate between reversible and irreversible etiologies.
We undertook a review of outcomes in one large center with stable referral patterns and stable patterns of practice to provide a contemporary benchmark for mortality in this population of infants and to establish etiologies of the failures to respond to standard therapies. We also sought to determine if there were easily identifiable predictors of mortality in this population. The approval by the Food and Drug Administration (FDA) of inhaled nitric oxide (iNO) for treatment of HRF in term and near-term infants in December 1999 served as a useful beginning point for the current study.
Methods

Clinical setting
The Intensive Care Nursery (ICN) of Children's Mercy Hospitals and Clinics in Kansas City, Missouri is a Level 3C ICN, 2 serving as a regional referral center for infants at risk for requiring extracorporeal membrane oxygenation (ECMO). The ECMO program has existed since 1987, managed by a single individual (BH). It is and has been the only ECMO program in western Missouri and the state of Kansas during this time.
Eligible infants
Records of all infants referred to Children's Mercy Hospital for the 6-year period from 1 January 2000 through 31 December 2005 were screened. The data extraction process was approved by the Children's Mercy Hospitals and Clinics Institutional Review Board (IRB). All data abstracted from the records were coded to assure anonymity. All patients were out born, with a referral distance of 0.1 to 200 miles. Records of all transports, including those in which the infant expired at the referring hospitals, were also reviewed.
Infants with gestational age X36 week, assessed on admission, without regard to birth weight, who were admitted to Children's Mercy Hospital in the first 72 hours after birth were evaluated. Only infants who required assisted ventilation for X24 hours were evaluated further. Infants treated only with continuous positive airway pressure (CPAP) were not included. Infants with complex malformations, including congenital diaphragmatic hernia, complex congenital cardiac lesions or abdominal or neurological disorders, were excluded.
Infants with perinatal depression and acidosis as the principal cause for assisted ventilation were excluded. Depression/acidosis was defined as a combination of Apgar scores at X5 minutes of p3, metabolic acidosis in the first 30 minutes of life with calculated base deficits X15 mmol/l, clinical appearance of comatose state and a decision by X2 attending neonatologists that the infant was ineligible for ECMO if he/she were to meet oxygenation criteria for ECMO, based on severity of neurologic exam and history.
Oxygenation Index (OI) All arterial blood gas tension measurements were matched with the FIO 2 and the mean airway pressure (MAP) recorded at the time of the blood gas tension determination. Only arterial samples were evaluated. OI were then calculated using the formula (FIO 2 Â 100) Â MAP (cm H 2 O)/P aO 2 . All arterial blood gas tension measurements made during the first 72 hours following admission were evaluated and the highest or worst OI for each patient was identified. Infants were categorized according to their worst OI, by disease category and by outcome, including need for ECMO. Management of ventilatory support during transport was provided by staff or faculty Neonatologists by telephone with ventilation adjustments made as needed during transport. iNO was also available and could be used during transport.
General management and use of ECMO ECMO was instituted only after there was minimal or transient response to other interventions, including sedation, normalization of blood pressure for age with use of dopamine and/or dobutamine infusions, treatment of metabolic and/or respiratory acidosis to achieve pH of 7.35 to 7.45 with P CO 2 <50 mm Hg. All infants received antibiotics. iNO treatment was started at 20 p.p.m. and not increased. The combination of high-frequency oscillatory ventilation with iNO was utilized if the infant was not responding to iNO. 3 If a sustained increase in P aO 2 occurred, as we have defined previously, 4 then stepwise reductions of FIO 2 , iNO and MAP all occurred. No infant demonstrated airway NO 2 levels >3.5 ppm, or plasma methemoglobin levels >3.5%.
Failure to demonstrate any improvement in P aO 2 or to maintain arterial P aO 2 X40 to 45 mm Hg with MAP X18 cm H 2 O with either conventional or high-frequency ventilation led to preparation for institution of ECMO. All infants had echocardiograms and head ultrasound examinations performed and underwent correction of pulmonary air leaks, if necessary, before cannulation. ECMO was exclusively veno-arterial. Parental consent was given for all infants recommended for ECMO. In all infants in whom ECMO was indicated, bypass was successfully initiated. iNO was discontinued once ECMO therapy was established. Utilizing our previously described standardized approach for assessing ongoing need for ECMO, 5 the attending neonatologist would begin the process of testing for successful separation from the ECMO circuit after 3 to 7 days of treatment.
Statistical evaluation
The 95% confidence intervals (CIs) for each mortality rate were calculated according to standard methods. 6 
Results
In the 6-year period studied, a total of 630 patients (average 105 per year) were identified and their medical records were scanned for meeting the criteria established for inclusion. A total of 315 infants had primary diagnoses of HRF and 315 infants had other primary diagnoses, but were treated with >24 hours assisted ventilation. The frequency, distribution of the etiologies of the respiratory failure and total mortality for the infants with HRF Abbreviations: HRF, hypoxic respiratory failure; PPHN, persistent pulmonary hypertension of the newborn. The diagnosis 'respiratory distress syndrome' was used for infants with radiographic findings of bilateral pulmonary densities and air bronchograms and no history of aspiration or infection. a 29 (50%) treated with ECMO; overall survival was 65%. b Both deaths were from pulmonary hypoplasia.
and for the infants with other primary diagnoses are presented ( Table 1 ). The infants with HRF as a secondary problem to the other disorders noted ( Table 1 ) represent subsets of all infants admitted with the disorders listed; many of these infants would not have required assisted ventilation, or would have required it for <24 hours. The range of worst OI for the HRF infants was expressed as p14, 15 to 25, and >25 (utilizing the approach of Kumar et al. 7 ). A total of 67 of the 315 infants with HRF as the primary diagnosis demonstrated worst OI of>25, and a total of 138 infants had a worst OI of >15 (Table 2 ). All infants with OI >25 were treated with iNO.
Use of ECMO for the HRF patient
A total of 32 infants (48% of those with OI >25) were treated with ECMO. A total of 28 (87.5%)survived to discharge. All ECMO survivors underwent head CT exams before discharge: six of 28 survivors demonstrated unilateral hemorrhage or infarct. In no case was the abnormal CT finding correlated with focal findings detectable by physical examination at discharge.
Overall mortality
Mortality for the 138 infants with HRF and with OI X15 was four of 138 or 2.9%. (95% CI: 0 to 5.7%). Mortality for infants with OI >25 was four of 67 or 6.0% (95% CI: 0 to 11.7%). Total mortality for infants treated for X24 hours of assisted ventilation for the 6-year period was 1.3% (95% CI: 0 to 2.5%).
Data from the Extracorporeal Life Support Organization (ELSO) provide a comparison to our data for survival (Table 3) . Etiologies for the respiratory failure for the infants treated with ECMO are provided by the registry. 8 
Details of deceased patients
Four infants with primary HRF died ( Table 1 ). All had been treated with ECMO. Two infants had septic shock associated with group B Streptococcus (GBS) and with Pseudomonas infections. Two other infants had apparently irreversible illness: alveolar capillary dysplasia (postmortem diagnosis) in an infant who had been categorized initially as 'RDS', and airway and alveolar hypoplasia and alveolar simplification identified from lung biopsy performed on ECMO in an infant who had been categorized initially as 'PPHN'.
Discussion
The 6-year period reviewed in this report was examined for several reasons. The approval by the FDA of iNO for treatment of HRF in term and near-term infants occurred in December 1999. Thus, the epoch examined represents the period following FDA approval of a therapy designed specifically for the disorders encountered in the current review. iNO had been demonstrated to reduce need for ECMO, although without reducing mortality. The local pattern of referrals to our center has been stable during this time. There had been no change during this time in local indications for use of ECMO.
Overall survival rates for ECMO-eligible infants with HRF have increased over the past 15 years. The UK collaborative trial of neonatal ECMO, 9 studying infants born between 1993 and 1995, reported overall mortality of 50 out of 150 (33%) of ECMO-eligible infants, excluding those with CDH. Cochrane analysis of trials of iNO conducted in the 1990s reported mortality rates of 9.7% (95% CI: 7.8 to 11.4%) in a population of 916 ECMO-eligible infants.
10 Limiting the analysis to the three large studies (NINOS, 11 Davidson et al., 12 and Clark et al. 13 ), provides a mortality rate of 57 out of 606 or 9.4%, 95% CI: (5.8 to 13.0%). More recently published trials (Kumar et al., 7 Konduri et al. 14 Guthrie et al. 15 ) reporting on term and near-term infants with OI X15 with HRF demonstrated a combined mortality of 7.2% (70 out of 975), 95% CI: 5.6 to 8.9%. In a single-center report, Gupta et al. 16 reported a mortality of 17/229 (7.0%), 95% CI: (3.7 to 10.3%) in their population of infants. Our 138 patients with OI X15 now add to the published total, but do not demonstrate a single optimal approach.
There are limitations in the comparison of the cited randomized trials to the present single referral center-based study. These limitations include the different time periods, the differing entry criteria and the exclusion of unstable infants requiring urgent ECMO treatment from the randomized trials; patients in latter category were included in the current analysis. In arriving at an understanding of current best practice, there is a benefit from the availability of results of many types of studies: prospective interventional trials, single referral center summaries of experience, and actual population-based surveys. With no new potentially highly efficacious therapies for these infants nearing FDA approval, this is a relevant time to identify best practices for limiting morbidity and mortality.
Another reason for performance of this study was to determine the incidence of currently untreatable conditions, which are not clinically obvious in the first hours or day following delivery. Two infants of the 32 who were unresponsive to all other therapies short of ECMO were diagnosed with irreversible disorders. No survivor of ECMO has demonstrated evidence of a progressive pulmonary disorder. Thus, the incidence of untreatable diseases is low in our referral population.
There are limitations to this study. The referral area of western and northwestern Missouri and almost all of Kansas has had a relatively stable annual birth total of approximately 55,000 per year for the years examined. This report is not a population-based study. Patients may have been referred to ECMO centers outside this region, to other Intensive Care Nurseries, or they may have died before transport could be arranged or accomplished. However, discussions with physicians at other centers, which might have received patients from this region, revealed no infant who was referred to another center who met inclusion criteria. Review of the Children's Mercy Hospitals and Clinics Transport Team records revealed no patients who died before their arrival who would have qualified for inclusion in this database. However, infants who might have been included in this review may have died in local hospitals even before transport could be arranged, or before a definitive diagnosis could be established. Similarly, infants whose disorders developed or became severe beyond the time period identified in the report were not included as the focus was on perinatal disorders.
Summary
Among the group of near-term or term infants requiring assisted ventilation for more than 24 h and with a peak OI of 25, only a small number manifest currently irreversible disorders. Given the survival rate achievable with current technology, substantial further mortality improvement may be difficult to attain.
